ClinicaliQ Trial Snapshot
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors — Recruiting • Phase II • Oncology • NCT06943755.
- Treatment being tested: Zanzalintinib (a novel investigational agent) is being compared directly against everolimus (current standard of care) in patients with advanced neuroendocrine tumors who have already received prior treatment.
- Patient eligibility overview: The trial includes adults with unresectable, locally advanced, or metastatic neuroendocrine tumors that have progressed despite previous treatment, representing a population with limited therapeutic options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Eligibility Snapshot
- Key Inclusion Criteria: * Histologically confirmed, locally advanced/unresectable or metastatic, well-differentiated Grade 1, 2, or 3 NETs of pancreatic origin or extra-pancreatic origin. * Allowed prior lines of therapy, based on the site of NET and functional status. * Documented radiographic disease progression per RECIST 1.1, as assessed by the Investigator based on imaging assessments (computed tomography [CT] or magnetic resonance imaging [MRI]) within 12 months before randomization. * Measurable disease according to RECIST 1.1 as determined by the Investigator. * Archival tumor tissue is required, if available. If archival tumor tissue is not available, a fresh biopsy may be submitted if it can be safely and feasibly obtained. Every attempt should be made to provide tumor tissue. Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.